MPPE1 and metabolic dysfunction-associated steatohepatitis: Importantly, blocking the infiltration of hepatic cDC1 by using XCL1 antibody in mice fed with CDHFD resulted in a moderate decrease in NASH pathology as compared to the isotype control-treated group (66).